DIPENTUM

This brand name is authorized in United States. It is also authorized in Australia, Canada, Finland, France, Ireland, Netherlands, New Zealand, South Africa.

Active ingredients

The drug DIPENTUM contains one active pharmaceutical ingredient (API):

1	Olsalazine UNII Y7JEW0XG7I - OLSALAZINE SODIUM
	Olsalazine is bioconverted to 5-aminosalicylic acid (5-ASA), which has anti-inflammatory activity in ulcerative colitis. The conversion of olsalazine to mesalamine (5-ASA) in the colon is similar to that of sulfasalazine, which is converted into sulfapyridine and mesalamine. The mechanism of action of mesalamine (and sulfasalazine) is unknown, but appears to be topical rather than systemic.
	Read more about Olsalazine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DIPENTUM Capsule	MPI, US: SPL/Old	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A07EC03	Olsalazine	A Alimentary tract and metabolism → A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents → A07E Intestinal antiinflammatory agents → A07EC Aminosalicylic acid and similar agents
Discover more medicines within A07EC03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	1728Y, 8086N
CA	Health Products and Food Branch	02063808
FI	Lääkealan turvallisuus- ja kehittämiskeskus	531956
FR	Base de données publique des médicaments	63634128, 64457645
IE	Health Products Regulatory Authority	21782, 21828
NL	Z-Index G-Standaard, PRK	25577, 32697
NZ	Medicines and Medical Devices Safety Authority	5127, 5129
US	FDA, National Drug Code	0037-6860
ZA	Health Products Regulatory Authority	V/11.9.2/301